Skip to main content

For Industry

You are here

UM Ventures Investments

University of Maryland Ventures, Baltimore invests in UMB startups based on innovative technologies with promising commercial potential. 
 
We also work closely with our startups to help expand and accelerate new business ventures. Our experienced business development team helps guide the development of go-to-market strategies and business plans, forms management teams, and identifies and helps secure funding.
  • Medcura

    A clinical-stage medical device company developing advanced hemostatic and wound treatment products. In 2019, Medcura received FDA Breakthrough...

     •  Visit Website
  • SurgiGyn, Inc.

    SurgiGYN is developing the uterine electrosurgical device (UED) to improve the safety and ease of total laparoscopic hysterectomy.

     •  Visit Website
  • NeoProgen, Inc.

    A preclinical stage company developing a novel cell-based therapy for cardiovascular disease, NeoProgen completed a $1.5M seed funding round.

     •  Visit Website
  • Gliknik Inc.

    Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders.

     •  Visit Website
  • Breethe, Inc.

    Breethe is working to develop and commercialize the world's first wearable artificial lung. Breethe was acquired by Abiomed in April 2020.

     •  Visit Website
  • Living Pharma, Inc.

    Living Pharma develops Personalized CAR T Cell Therapy™. In 2017, 18 months after forming, Lentigen Technology, Inc. acquired Living Pharma.

     •  Visit Website
  • CoapTech

    Developing the first FDA-cleared, ultrasound-based solution for feeding tube placement, CoapTech recently received a $1.2M NIH grant.

     •  Visit Website
  • Protaryx Medical

    Protaryx is reimagining access to the left atrium for transcatheter cardiac procedures, and raised an $8.3M Series A round led by Ajax Health.

  • NextStep Robotics

    This early-stage company developing a personalized robotic therapy for recovering stroke patients was awarded a $1M NIH Cooperative Agreement.

     •  Visit Website
  • Isoprene Pharmaceuticals

    Isoprene Pharmaceuticals is an early-stage small molecule oncology company developing oral therapeutics for triple negative breast cancer and other...

Pages